At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Antiviral Activity, and Pharmacokinetics of Multiple Rising Oral Doses of BI 201335 NA in Treatment-naïve Patients With Chronic Hepatitis C Infection for 14 Days Monotherapy Followed by Combination With Pegylated Interferon and Ribavirin for an Additional 14 Days (Double-blind, Placebo Controlled), and in Treatment-experienced Patients With Chronic Hepatitis C Infection for 28 Days as Combination Therapy With Pegylated Interferon and Ribavirin (Open-label)
In Brief
A Phase 1 clinical trial evaluating BI201335 and Placebo for Hepatitis C, Chronic. Completed, enrolled 96 participants across 16 sites in 4 countries.
Detailed Summary
This study will investigate safety, antiviral activity, and pharmacokinetics of BI 201335 NA in HCV genotype 1 infected patients treated for 14 days monotherapy followed by BI 201335 NA combination therapy with PegIFN/RBV for an additional 14 days for treatment-naïve patients; or for 28 days as BI 201335 NA combination therapy with PegIFN/RBV for treatment-experienced patients. A secondary objective is to investigate antiviral activity, potential drug-drug interactions and safety of combination therapy of BI 201335 NA and PegIFN/RBV up to 28 days for treatment-naïve patients.
Study Details
Timeline
Interventions
patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days